Johnson & Johnson: Janssen to Highlight Depth of Solid Tumor Portfolio at American Society of Clinical Oncology Genitourinary
February 04, 2020
February 04, 2020
RARITAN, New Jersey, Feb. 4 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, issued the following news release:
* * *
- New data featured in multiple presentations across prostate and bladder cancer treatment portfolio and pipeline including ERLEADA (apalutamide), niraparib and BALVERSATM (erdafitinib)
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from a robu . . .
* * *
- New data featured in multiple presentations across prostate and bladder cancer treatment portfolio and pipeline including ERLEADA (apalutamide), niraparib and BALVERSATM (erdafitinib)
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from a robu . . .